title: [Antitumor activity of dioxadet compared with cisplatin on ascitic ovarian tumor in rats].
abstract: Antitumor activity of dioxadet in comparison with cisplatin was studied on the model of ascitic ovarian tumor in 32 female Wistar rats. Ascitic ovarian tumor was transplanted intraperitoneally 0.5 ml per rat dissolved by saline in ratio 1 to 4. Dioxadet (1.5 mg/kg b.w.) and cisplatin (4.0 mg/kg b.w.) were administered intraperitoneally at their single maximal tolerable doses 48 hours after tumor cells transplantation. For drug activity estimation time to ascites detection and survival time values were used. In control group without no treatment the time till ascites occurrence and median life span were 5.4 +/- 0.25 and 7.5 days, correspondingly. In comparison with the control group dioxadet increased the average time of ascites occurrence and median of life span by 30% and 113% (p < 0.05), cisplatin increased these parameters by 28% and 147% (p < 0.05). Hence, antitumor activity of dioxadet is comparable with cisplatin activity for intraperitoneal therapy of the ascitic ovarian tumor.
authors.forename: V G
authors.initials: VG
authors.lastname: Bespalov
authors.forename: O A
authors.initials: OA
authors.lastname: Beliaeva
authors.forename: A V
authors.initials: AV
authors.lastname: Panchenko
authors.forename: A N
authors.initials: AN
authors.lastname: Stukov
authors.forename: M L
authors.initials: ML
authors.lastname: Gershanovich
authors.forename: Ia G
authors.initials: IaG
authors.lastname: Murazov
authors.forename: S A
authors.initials: SA
authors.lastname: Kon'kov
authors.forename: N E
authors.initials: NE
authors.lastname: Kil'maeva
authors.forename: I M
authors.initials: IM
authors.lastname: Krylova
authors.forename: T A
authors.initials: TA
authors.lastname: Mironiuk
authors.forename: D Kh
authors.initials: DKh
authors.lastname: Latipova
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001201:Ascites / Q000209:etiology*; D002945:Cisplatin / Q000494:pharmacology*; D005260:Female; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy*; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome; D014227:Triazines / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D014227:Triazines; C040269:dioxadet; D002945:Cisplatin